PMV Pharmaceuticals, Inc.PMVP
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · pmvpharma.com
PMV Pharmaceuticals is a precision oncology company headquartered in Princeton, New Jersey, pioneering the discovery and development of small molecule therapies targeting p53, a protein whose mutations are found in approximately half of all cancers. Its lead candidate rezatapopt is in the PYNNACLE Phase 2 pivotal trial.
Key ratios
ROA
-35.0%2025
2024
-22.2%2023
-19.2%
ROE
-55.4%2025
2024
-29.2%2023
-29.2%
Recent news
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
PMV Pharma Announces Proposed Public Offering of Securities
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
Track PMVP in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer